ROCHE HLDGS AG SPN ADR EACH REP 0.125GENUS (RHHBY)

34.30
0.13 0.38
OTC
Prev Close 34.43
Open 34.43
Day Low/High 34.27 / 34.47
52 Wk Low/High 25.25 / 36.82
Volume 608.03K
Exchange OTC
Shares Outstanding 5620.50B
Market Cap 192.76B
Div & Yield N.A. (N.A)

Latest News

Merck KGaA Edges Full-Year Guidance Higher After Solid Q1 Earnings

Merck KGaA Edges Full-Year Guidance Higher After Solid Q1 Earnings

Merck KGaA posted slightly stronger-than-expected first quarter earnings Thursday and nudged its full-year profit guidance higher after a key drug approval in the United States.

Genentech To Present New Data On Personalized Medicines And Cancer Immunotherapies At The 2017 American Society Of Clinical Oncology (ASCO) Annual Meeting

Genentech To Present New Data On Personalized Medicines And Cancer Immunotherapies At The 2017 American Society Of Clinical Oncology (ASCO) Annual Meeting

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced new data on 20 approved and investigational medicines will be presented during the American Society of Clinical Oncology (ASCO) Annual...

Merck Extends Immunotherapy Lead With Lung Cancer Combination Therapy Approval

Merck Extends Immunotherapy Lead With Lung Cancer Combination Therapy Approval

Keytruda is now the only PD-1 or PD-L1 checkpoint inhibitor approved to treat first-line lung cancer either as monotherapy or as part of a combination therapy.

Cancer Immunotherapy Fallout From Roche's Bladder Cancer Failure

Cancer Immunotherapy Fallout From Roche's Bladder Cancer Failure

Will the FDA revoke Roche's accelerated approval for Tecentriq in bladder cancer?

Roche's Loss In Bladder Cancer Lifts Astrazeneca and Could Boost Bristol-Myers

Roche's Loss In Bladder Cancer Lifts Astrazeneca and Could Boost Bristol-Myers

Roche, the Swiss drugmaker, was let down by Tecentriq in clinical trials providing scope for Astra to close the gap and a possible boost for Bristol on Wednesday

European Stocks Drift Lower as Trump's Move to Fire FBI Director Comey Tapers Bulls

European Stocks Drift Lower as Trump's Move to Fire FBI Director Comey Tapers Bulls

European stocks drifted lower Wednesday as investors trim bets in the region amid multi-year highs after President Donald Trump fired his FBI Director James Comey.

Roche Receives FDA Approval For Complementary PD-L1 (SP263) Biomarker Test In Urothelial Carcinoma

Roche Receives FDA Approval For Complementary PD-L1 (SP263) Biomarker Test In Urothelial Carcinoma

- Urothelial carcinoma, the most common type of bladder cancer, is the fourth most common cancer in men in the United States[1]

FDA Clears Roche High-volume Immunoassay Lab Testing Solution To Support Critical Medical Treatment Decisions

FDA Clears Roche High-volume Immunoassay Lab Testing Solution To Support Critical Medical Treatment Decisions

cobas® e 801 module delivers on the promise of next-generation laboratory efficiency

Roche Tops the Swiss Market After First Quarter Sales Beat Expectations

Roche Tops the Swiss Market After First Quarter Sales Beat Expectations

Sales rose 4% and were 2% ahead of expectation on strong sales from core drugs and promising results from new treatments.

New Data At AAN Reinforce Clinical Benefit Of Genentech's OCREVUS (Ocrelizumab) For Relapsing And Primary Progressive Multiple Sclerosis

New Data At AAN Reinforce Clinical Benefit Of Genentech's OCREVUS (Ocrelizumab) For Relapsing And Primary Progressive Multiple Sclerosis

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that new data from the OCREVUS™ (ocrelizumab) clinical trial programs will be presented during the 69th American Academy of...

What to Expect From European Pharmaceuticals' First Quarter Results

What to Expect From European Pharmaceuticals' First Quarter Results

New drug launches and late stage trials will be under the microscope as eight European pharmaceuticals companies report Q1 earnings starting next week.

Roche Diagnostics Recognizes Sentara Consolidated Laboratories As Roche Molecular Center Of Excellence

Roche Diagnostics Recognizes Sentara Consolidated Laboratories As Roche Molecular Center Of Excellence

Institution joins strategic network designed to help accelerate advancement of new methods in molecular diagnostics, anatomic pathology and sequencing

Genentech To Present New Data At AAN Reinforcing Efficacy And Safety Of Newly FDA Approved OCREVUS (Ocrelizumab) In Two Types Of Multiple Sclerosis

Genentech To Present New Data At AAN Reinforcing Efficacy And Safety Of Newly FDA Approved OCREVUS (Ocrelizumab) In Two Types Of Multiple Sclerosis

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that new data on OCREVUS™ (ocrelizumab) in people with relapsing forms of multiple sclerosis (RMS) and primary progressive MS (PPMS)...

FDA Grants Genentech's TECENTRIQ (Atezolizumab) Accelerated Approval As Initial Treatment For Certain People With Advanced Bladder Cancer

FDA Grants Genentech's TECENTRIQ (Atezolizumab) Accelerated Approval As Initial Treatment For Certain People With Advanced Bladder Cancer

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.

FDA Approves Genentech's Lucentis (Ranibizumab Injection) For Diabetic Retinopathy, The Leading Cause Of Blindness Among Working Age Adults In The United States

FDA Approves Genentech's Lucentis (Ranibizumab Injection) For Diabetic Retinopathy, The Leading Cause Of Blindness Among Working Age Adults In The United States

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.

Genentech Announces Positive Interim Results For Emicizumab In Phase III Study Of Children With Hemophilia A

Genentech Announces Positive Interim Results For Emicizumab In Phase III Study Of Children With Hemophilia A

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced interim results from the Phase III HAVEN 2 study evaluating emicizumab prophylaxis in children less than 12 years of age with hemophilia A...

Protalix Cystic Fibrosis Drug Study Results Worsen Over Time

Protalix Cystic Fibrosis Drug Study Results Worsen Over Time

The Protalix medicine alidornase alfa is designed to help cystic fibrosis patients clear their lungs by making mucus thin and loose.

Roche Launches New Global Certified Provider Program For Target Enrichment In Genomic Sequencing

Roche Launches New Global Certified Provider Program For Target Enrichment In Genomic Sequencing

-- Program helps meet customers' needs for both basic and clinical research applications

Phase III Study Shows Genentech's Alecensa® Was Superior To Crizotinib In A Specific Type Of Lung Cancer

Phase III Study Shows Genentech's Alecensa® Was Superior To Crizotinib In A Specific Type Of Lung Cancer

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the global, randomized Phase III ALEX study met its primary endpoint and showed that Alecensa ® (alectinib) as an initial...

Mylan Has Been Pounded, but the Pain May be Far from Over

Mylan Has Been Pounded, but the Pain May be Far from Over

The maker of the EpiPen seems incapable of overcoming its troubles.

Incyte Cancer Immunotherapy Drug Is Object of Desire for Two Big Pharma Rivals

Incyte Cancer Immunotherapy Drug Is Object of Desire for Two Big Pharma Rivals

The broad development plan across five different types of cancer widens Incyte's lead over other IDO inhibitors in clinical development.

FDA Advisory Committee Unanimously Recommends Approval Of Genentech's Subcutaneous Rituximab For Certain Blood Cancers

FDA Advisory Committee Unanimously Recommends Approval Of Genentech's Subcutaneous Rituximab For Certain Blood Cancers

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.

Roche Wins FDA Backing for New Multiple Sclerosis Therapy, Competition Could Crimp Biogen

Roche Wins FDA Backing for New Multiple Sclerosis Therapy, Competition Could Crimp Biogen

The Roche drug, Ocrevus, secured FDA approval for two forms of multiple sclerosis.

FDA Approves Genentech's OCREVUS™ (Ocrelizumab) For Relapsing And Primary Progressive Forms Of Multiple Sclerosis

FDA Approves Genentech's OCREVUS™ (Ocrelizumab) For Relapsing And Primary Progressive Forms Of Multiple Sclerosis

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.

Merck KGaA Shares Spike After FDA Approves Skin Cancer Treatment

Merck KGaA Shares Spike After FDA Approves Skin Cancer Treatment

Merck KGaA shares tested one-year highs Friday after the Food & Drug Administration approved rare form of skin cancer treatment that could cost patients as much as $13,000 per month.

FDA Grants Breakthrough Therapy Designation For Rituxan® (Rituximab) In Pemphigus Vulgaris

FDA Grants Breakthrough Therapy Designation For Rituxan® (Rituximab) In Pemphigus Vulgaris

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.